In the context of glioblastoma, the inhibition of FTO rather than METTL3 or METTL14 was shown to inhibit the proliferation of glioblastoma stem cells (GSCs) and tumorigenesis through the modulation of various oncogenes (ADAM19, EPHA3, and KLF4), tumor suppressors (CDKN2A, BRCA2, and TP53I11), and neural cell markers (GFAP, TUBB3) [74]. The gene discussed is METTL3; the disease is glioblastoma.